Med-tech business, Bedfont, donates life-saving FeNO monitor to asthma charity

MAIDSTONE, U.K. - Oct. 24, 2019 - PRLog -- An increasing concern, asthma is a chronic respiratory disease that causes difficulty in breathing and is estimated to affect 5.4 million people in the UK. Asthma was responsible for more than 1400 deaths last year - the highest point for a decade, having increased by more than 33% over the last 10 years, yet 2/3 of asthma deaths could have been prevented by better basic care; something that Bedfont is hoping to achieve with the NObreath FeNO monitor.

Conformed to ATS and ERS guidelines, the NObreath is ideal for patients and GPs as it uses quick, easy and non-invasive breath analysis to aid in the diagnosis and management of asthma. Interpreting FeNO levels aids in identifying patients who do/do not require on-going treatment, helps to assess inhaler technique, aids in differentiating between allergic (eosinophilic) and non-allergic asthma, and if used daily, FeNO measurements can help to predict exacerbations and attacks.

MASH, based in Gillingham, has been established since 1996 and helps asthma patients in the Medway Council area by providing information on asthma, and, in close cooperation with Primary Care and other NHS services, a diagnostic and management service for adults and children. The charity offers appointments with a specialist asthma nurse, offers asthma allergy testing and lung function testing, and provides advice on treatment and using inhalers.

Jason Smith, Managing Director at Bedfont, explains, "With asthma related deaths at an all-time high, FeNO monitoring needs to be included in basic asthma care more than ever. We have decided to donate a NObreath to MASH, which is great charity that supports people in our local community, some of whom actually work for Bedfont. Hopefully with a NObreath to aid their services, more people can receive a quick diagnosis and more detailed treatment after knowing their FeNO levels and their asthma subtype has been differentiated."

Dr Martin Farebrother, a Trustee of MASH, adds, "As a retired physician specialising in respiratory medicine, I am only too well aware of the difficulties of diagnosis and management in some asthmatics. Measurement of FeNO has added significantly to the ability to determine the correct diagnosis and the best care. Bedfont are leaders in this field and their monitor is recognised as meeting the highest standards. At MASH we welcome this generous donation from Bedfont, and we look forward to working with them to improve our ability to provide the best service to these people. This cooperation is especially appropriate because they are a locally based company."